Novartis (NVS) said Thursday it has rolled forward its mid-term sales outlook to 2025-2030 with a sales compound annual growth rate of more than 5% to 6%.
The company has also upgraded outlook for its brands, including Kisqali and Scemblix, it said, adding that its mid-term outlook for Kisqali is raised to over $10 billion from more than $8 billion, while Scemblix is raised to over $4 billion from more than $3 billion, previously.
The medicines company said it is "well positioned" for growth beyond 2030.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments